These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35005818)

  • 1. Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973.
    Arvanitakis A; Holme PA; Berntorp E; Astermark J
    Haemophilia; 2022 Mar; 28(2):223-229. PubMed ID: 35005818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
    Arvanitakis A; Berntorp E; Astermark J
    Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
    Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Solms A; Wang M
    Eur J Haematol; 2020 Aug; 105(2):164-172. PubMed ID: 32259334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
    Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Wu R; Chen Z
    Haemophilia; 2021 May; 27(3):e340-e346. PubMed ID: 33645868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
    Nagao A; Yeung CHT; Germini F; Suzuki T
    Thromb Res; 2019 Jan; 173():79-84. PubMed ID: 30496937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
    Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAY 81-8973 (Octocog Alfa; Kovaltry
    Keating GM
    BioDrugs; 2016 Oct; 30(5):453-459. PubMed ID: 27577234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.
    Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Tueckmantel C; Cabre-Marquez JF; Wang M
    Eur J Haematol; 2023 Jan; 110(1):77-87. PubMed ID: 36192847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973).
    Cortesi PA; Di Minno G; Zanon E; Giuffrida G; Santoro RC; Marino R; D'Angiolella LS; Antonazzo IC; Squassabia G; Clemente F; Di Laura D; Cimino E; Pasca S; Nicolosi D; Mantovani LG
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.